Traumatic Intracranial Hemorrhage in Users of Oral Antithrombotic Drugs

Traumatic Intracranial Hemorrhage in Users of Oral Antithrombotic Drugs: a Nationwide Pharmacoepidemiological Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02996851

Enrollment

6279

Registered

2016-12-19

Start date

2007-01-31

Completion date

2014-12-31

Last updated

2017-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Embolism and Thrombosis, Hematoma, Subdural, Intracranial, Intracranial Hemorrhage, Traumatic

Keywords

Fibrinolytic Agents, Adverse effects, Norway, Registries

Brief summary

Oral antithrombotic medications (OAM) are used for the prevention and treatment of thrombotic disorders. Among hemorrhagic complications of OAMs, intracranial hemorrhage (ICH) may have particularly devastating consequences with high morbidity, disability and mortality rates. The efficacy and safety profiles of OAMs are generally assessed in randomized controlled trials (RCT), but included patients are often highly selected and may not be representative of users in everyday clinical practice in terms of follow-up routines, age, gender, drug compliance, and polypharmacy. Moreover, it is often unclear whether or not traumatic ICHs are registered and reported in RCTs. Drifts in indications and treatment criteria may also be seen in everyday practice and drug discontinuation due to precautionary concerns including compliance, fall risk and comorbidity may be forgotten. Collectively, these factors may lead to other and potentially higher traumatic ICH rates in general clinical use than reported in RCTs. The incidence rates of traumatic ICH in patients on OAMs in the general population remain unknown. In this nationwide registry based pharmacoepidemiological study we will investigate the incidence and case fatality of traumatic ICH in users of OAMs in Norway from 2008 through 2014.

Interventions

None listed

Study design

Observational model

ECOLOGIC_OR_COMMUNITY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* included in the Norwegian patient registry (NPR) and/or the Norwegian prescription database (NorPD)

Exclusion criteria

Design outcomes

Primary

Measure	Time frame	Description
incidence of intracranial hemorrhage requiring hospital admission	at least 12 months following intracranial hemorrhage	Age- and gender-adjusted comparisons of annual incidence rates will be carried out

Secondary

Measure	Time frame	Description
incidence of fatal traumatic intercranial hemorrhage defined as death within 90 days of admission	90 days	Age- and gender-adjusted comparisons of annual incidence rates will be carried out.
overall survival following traumatic intracranial hemorrhage	6 years	—

Outcome results